IPO Year: 2023
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Neutral → Underperform | BofA Securities | |
| 10/14/2024 | Buy → Neutral | BofA Securities | |
| 8/16/2023 | Market Perform | SVB Securities | |
| 8/15/2023 | $20.00 | Overweight | Piper Sandler |
| 8/15/2023 | $18.00 | Buy | BofA Securities |
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the addition of Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Weber will work with Turnstone's SAB and management team to provide strategic, scientific, and clinical guidance to advance the Company's pipeline of Selected TIL therapies, which are designed to selectively expand the most potent tumor-reactive T cells and extend the benefit of TILs to a w
10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
S-8 - Turnstone Biologics Corp. (0001764974) (Filer)
10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
BofA Securities downgraded Turnstone Biologics from Neutral to Underperform
BofA Securities downgraded Turnstone Biologics from Buy to Neutral
SVB Securities initiated coverage of Turnstone Biologics with a rating of Market Perform
Piper Sandler initiated coverage of Turnstone Biologics with a rating of Overweight and set a new price target of $20.00
BofA Securities initiated coverage of Turnstone Biologics with a rating of Buy and set a new price target of $18.00
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
3 - Turnstone Biologics Corp. (0001764974) (Issuer)
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. "Earlier this quarter, we announced a corporate restructuring and the decision to focus resources on our Phase 1 program, TIDAL-01, which we believe puts us on the path to significant value creation. Importantly, our extended cash runway into the second quarte
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection a
Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced a strategic prioritization of its pipeline, as well as a workforce reduction of approximately 60% and changes to its leadership team, to focus resources on the contin
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. "We have continued to bolster our position
Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing successProduct characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. The presentation will begin at 11:35 a.m. P.T. / 2:35 p.m. E.T. To access a live webcast of the presentation, please visit the Events page in the Investors section of
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetingsSpeaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive OfficerDate: Wednesday, March 6, 2024Presentation Time: 2:10pm ET / 11:10am PTLocation: Bosto
Gainers Larimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock rose 6.53% to $8.31. The company's market cap stands at $11.4 million. As per the press release, Q1 earnings came out 3 days ago. DermTech (NASDAQ:DMTK) shares moved upwards by 5.52% to $0.38. The market value of their outstanding shares is at $13.2 million. As per the news, the Q1 earnings report came out 4 days ago. BiomX (AMEX:PHGE) shares rose 5.38% to $0.36. The company's market cap stands at $19.8 million. Sharecare (NASDAQ:SHCR) shares rose 4.99% to $0.88. The market value of their ou
Gainers Scorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 19.22% to $0.17. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out 2 days ago. Doximity (NYSE:DOCS) stock rose 11.4% to $26.45. The market value of their outstanding shares is at $4.9 billion. As per the news, the Q4 earnings report came out today. MEI Pharma (NASDAQ:MEIP) stock increased by 10.92% to $3.25. The company's market cap stands at $21.6 million. Akso Health Group (NASDAQ:AHG) stock increased by 9.36% to $0.69. The compan
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.78) by 8.97 percent.
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.86) by 15.12 percent.
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's market cap stands at $51.1 million. Taysha Gene Therapies (NASDAQ:TSHA) shares moved upwards by 29.36% to $2.91. The market value of their outstanding shares is at $544.1 million. The company's, Q4 earnings came out today. Moleculin Biotech (NASDAQ:MBRX) shares increased by 14.54% to $0.6. The market value of their outstanding shares is at $20.0 million. Turnstone Biologics (NASDAQ:TSBX) stock moved upwards by 11.5% to $3.49. The market value of their outstanding shares is at $80.5 million. Enveric Biosciences (NASDAQ:ENVB) shares rose 8.4% to $1.29. The company's m
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million. Ainos (NASDAQ:AIMD) stock moved upwards by 91.96% to $2.15. The company's market cap stands at $10.0 million. Mira Pharmaceuticals (NASDAQ:MIRA) shares increased by 34.75% to $1.28. The company's market cap stands at $18.9 million. Joint (NASDAQ:JYNT) stock rose 29.1% to $11.8. The market value of their outstanding shares is at $174.1 million. The company's, Q4 earnings came out yesterday. Lantern Pharma (NASDAQ:LTRN) stock rose 25.11% to $8.32. The market value of their outstanding shares is at $89.3 million.
Gainers Singular Genomics Sys (NASDAQ:OMIC) shares moved upwards by 17.9% to $0.66 during Friday's after-market session. The market value of their outstanding shares is at $48.4 million. Vaccinex (NASDAQ:VCNX) stock increased by 11.61% to $0.77. The company's market cap stands at $9.6 million. Celularity (NASDAQ:CELU) shares moved upwards by 7.52% to $0.46. The market value of their outstanding shares is at $99.5 million. ZyVersa Therapeutics (NASDAQ:ZVSA) stock rose 6.87% to $0.62. The company's market cap stands at $1.0 million. BioXcel Therapeutics (NASDAQ:BTAI) stock moved upwards by 5.21% to $2.22. The company's market cap stands at $66.4 million. Turnstone Biologics (NASDAQ:TSBX)
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares moved upwards by 46.5% to $1.67 during Tuesday's regular session. The market value of their outstanding shares is at $5.2 million. Turnstone Biologics (NASDAQ:TSBX) stock rose 33.55% to $3.0. The market value of their outstanding shares is at $69.3 million. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 33.08% to $3.54. The company's market cap stands at $57.9 million. Outlook Therapeutics (NASDAQ:OTLK) stock increased by 24.49% to $0.42. The company's market cap stands at $110.1 million. Jin Medical International (NASDAQ:ZJYL) stock rose 22.42% to $131.0. The company's market cap stands at $1.0 billion. Catheter Precision (AMEX:
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(1.00) per share. This is a 83.74 percent increase over losses of $(6.15) per share from the same period last year.
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $54.5 million. Werewolf Therapeutics (NASDAQ:HOWL) shares rose 20.0% to $2.58. The company's market cap stands at $91.9 million. Pasithea Therapeutics (NASDAQ:KTTA) stock rose 16.93% to $0.37. The market value of their outstanding shares is at $7.7 million. Altamira Therapeutics (NASDAQ:CYTO) shares moved upwards by 14.98% to $0.19. The company's market cap stands at $1.4 million. Arcutis Biotherapeutics (NASDAQ:ARQT) shares moved upwards by 13.96% to $2.53. The market value of their outstanding shares is at $238.2 million. As per th